40 us $ offer too low????I would take this and run.. Concordia needs to make a deal here.. Its a double for the current share holders, Apollo could wipe this debt out and generate tons of free cash flow.. over 1 billion $ in revenue and robust pipeline of 60 + drugs . I think its an excellent buy for any long term investor with a possilbility of a 100 % takeover premium in a very short time frame. Shares outstanding are less then 50 million and a huge short postion in this makes this a solid buy at these levels. Debt is nothing compared to valeant or other pharma companies .